Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Total Non-Current Liabilities (2016 - 2024)

Historic Total Non-Current Liabilities for BioCorRx (BICX) over the last 10 years, with Q4 2024 value amounting to $12.7 million.

  • BioCorRx's Total Non-Current Liabilities rose 2384.56% to $12.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $12.7 million, marking a year-over-year increase of 2384.56%. This contributed to the annual value of $12.7 million for FY2024, which is 2384.56% up from last year.
  • According to the latest figures from Q4 2024, BioCorRx's Total Non-Current Liabilities is $12.7 million, which was up 2384.56% from $12.6 million recorded in Q3 2024.
  • BioCorRx's Total Non-Current Liabilities' 5-year high stood at $12.7 million during Q4 2024, with a 5-year trough of $9.0 million in Q4 2022.
  • In the last 3 years, BioCorRx's Total Non-Current Liabilities had a median value of $11.3 million in 2024 and averaged $11.2 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 1471.43% in 2023, then skyrocketed by 2384.56% in 2024.
  • Over the past 3 years, BioCorRx's Total Non-Current Liabilities (Quarter) stood at $9.0 million in 2022, then increased by 14.71% to $10.3 million in 2023, then increased by 23.85% to $12.7 million in 2024.
  • Its Total Non-Current Liabilities stands at $12.7 million for Q4 2024, versus $12.6 million for Q3 2024 and $11.5 million for Q2 2024.